Clinical-stage biotechnology company BioTime, Inc., has entered into a global in-licensing agreement for a next-generation retinal disease therapy from the University of Pittsburgh Medical Center (UPMC), which could reportedly lead to fully-functional retinal tissue implants to restore vision in late stages of blindness.
The technology was reportedly developed in part in collaboration with BioTime scientists and includes composition and methodologies to develop 3D retinal tissue derived from human pluripotent stem cells for implantation in patients with advanced stages of retinal degeneration.
According to BioTime, the technology would allow them to generate 3D laminated human retinal tissue in a controlled manufacturing process, leading to vision restoration treatments for a number of blinding retinal degenerative diseases such as retinitis pigmentosa, macular degeneration, and diabetic retinopathy.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.